All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
There is a distinct set of challenges for patients who become pregnant and have a diagnosis of myeloproliferative neoplasms (MPN), as previously discussed on the MPN Hub. These patients have an increased risk of thrombosis and hemorrhage, especially during delivery and postpartum, in addition to consequences for fetal growth, including placental insufficiency, stillbirth, and premature delivery.1 As a result, complex management strategies are required to ensure the best possible maternal and fetal outcomes. Best practice recommendations for managing pregnant patients with MPN have previously been reported on the MPN Hub. Here, we outline common risks, challenges, and further practice recommendations in the management of this patient population.
Figure 1. Management strategies according to pregnancy stage in patients with MPN*
LMWH, low molecular weight heparin; MPN, myeloproliferative neoplasms.
*Adapted from Robinson and Harrison.2
Pregnant patients diagnosed with MPN require multidisciplinary management to ensure the strategies associated with each stage of pregnancy are implemented and optimized. While maternal and fetal outcomes are improving with current therapeutic options and risk-mitigating recommendations, further advancement and refinement of management strategies is warranted.